Prolacta Bioscience
PrivateLast Round
M&A
Dec 30, 2024
Total Funding Raised
$80.9M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Prolacta Bioscience is a life sciences company that develops and manufactures human milk-based nutritional products for critically ill and premature infants in neonatal intensive care units.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Medical Devices
Business Model
B2B
Customer Profile
Hardware Sales
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Prolacta Bioscience Comparables
Compare Prolacta Bioscience with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| LactaLogics | 78% | |
| Abbott Laboratories | 78% | |
| Medolac Laboratories | 76% |
Prolacta Bioscience Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| M&A | Dec 30, 2024 | ||||
| Series E | May 14, 2018 | ||||
| Series E | Dec 6, 2016 | ||||
| Series D | Nov 3, 2011 | ||||
| Series C | May 23, 2007 | ||||
Series B | Oct 4, 2006 |
Key People
Founding team and executive leadership
Prolacta Bioscience Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| DFJ Frontier | Series C |
| EW Healthcare Partners | M&A, Series E |
| Gideon Hixon Fund | Series C |
| Aisling Capital | Series E |
| Draper Associates | Series C |
| PhillipCapital Group | Series C |
| Arcturus Capital | Series C |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 20, 2026
Open roles increased to 328, 101% of current headcount.
- Jun 27, 2026
Product used by over 100,000 premature infants globally.
Recent news
Latest coverage and updates
- launchesSep 2, 2026
Prolacta Bioscience launched Prolact+ H2MF on Jul 1st '06.
Prolacta Bioscience Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Prolacta Bioscience's valuation, stock price, and market status.
Is Prolacta Bioscience a public or private company?
Prolacta Bioscience is a private company.
What is the current stock price of Prolacta Bioscience?
Prolacta Bioscience is a private company with no public stock price. No recent secondary market data is available.
How much is Prolacta Bioscience worth (valuation)?
Valuation information for Prolacta Bioscience is not publicly available.
Can I buy Prolacta Bioscience stock?
Prolacta Bioscience shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Prolacta Bioscience's last funding round?
Prolacta Bioscience's most recent funding round was M&A on December 30, 2024.
Who are the main investors in Prolacta Bioscience?
Key investors in Prolacta Bioscience include EW Healthcare Partners, Alta Partners.
Will Prolacta Bioscience IPO soon?
No public IPO plans have been announced for Prolacta Bioscience.
How can I track Prolacta Bioscience secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Prolacta Bioscience's secondary market activity and sign up for updates.